RISK FACTORS FOR RESPIRATORY SYNCYTIAL VIRUS BRONCHIOLITIS HOSPITALIZATIONS IN CHILDREN WITH CHRONIC DISEASES

2021 ◽  
Author(s):  
Einat Shmueli ◽  
Ori Goldberg ◽  
Meir Mei‐Zahav ◽  
Patrick Stafler ◽  
Ophir Bar‐On ◽  
...  
Keyword(s):  
Risk Factors ◽  
Respiratory Syncytial Virus ◽  
Chronic Diseases ◽  
Respiratory Syncytial Virus Bronchiolitis ◽  
Syncytial Virus

scholarly journals Burden of Respiratory Syncytial Virus Disease and Mortality Risk Factors in Argentina

2019 ◽  
Vol 38 (6) ◽  
pp. 589-594 ◽  
Author(s):  
Angela Gentile ◽  
María Florencia Lucion ◽  
María del Valle Juarez ◽  
María Soledad Areso ◽  
Julia Bakir ◽  
...  
Keyword(s):  
Risk Factors ◽  
Respiratory Syncytial Virus ◽  
Mortality Risk ◽  
Virus Disease ◽  
Respiratory Syncytial Virus Disease ◽  
Syncytial Virus

scholarly journals Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada

2021 ◽  
Author(s):  
Ian Mitchell ◽  
Abby Li ◽  
Candice L. Bjornson ◽  
Krista L. Lanctot ◽  
Bosco A. Paes ◽  
...  
Keyword(s):  
Risk Factors ◽  
Respiratory Syncytial Virus ◽  
Burden Of Illness ◽  
Respiratory Illness ◽  
Smoking Exposure ◽  
Key Points ◽  
Rsv Infection ◽  
History Of ◽  
Syncytial Virus ◽  
Airway Anomalies

Objective This study aimed to evaluate palivizumab (PVZ) use, trends in indications, and outcomes of respiratory illness hospitalizations (RIH) and respiratory syncytial virus hospitalizations (RSVH). Study Design It involves a large, Canadian prospective (2005–2017) observational multicenter study of children at high risk for RSV infection. Results A total of 25,003 infants (56.3% male) were enrolled at 32 sites; 109,579 PVZ injections were administered. Indications included: prematurity (63.3%); “miscellaneous” (17.8%); hemodynamically significant congenital heart disease (10.5%); bronchopulmonary dysplasia/chronic lung disease (8.4%). The “miscellaneous” group increased over time (4.4% in 2005–2006 to 22.5% in 2016–2017) and included: trisomy 21, airway anomalies, pulmonary disorders, cystic fibrosis, neurological impairments, immunocompromised, cardiac aged >2 years, multiple conditions, and a residual “unclassified” group. Adherence measured by expected versus actual doses plus correct interdose interval was 64.7%. A total of 2,054 RIH occurred (6.9%); 198 (9.6%) required intubation. Three hundred thirty-seven hospitalized children were RSV-positive (overall RSVH 1.6%). Risk factors for RSVH included having siblings, attending daycare, family history of atopy, smoking exposure, and crowded household. Infants with 5 risk factors were 9.0 times (95% CI or confidence interval 4.4–18.2; p < 0.0005) more likely to have RSVH than infants without risk factors. Three adverse events occurred; none were fatal. Conclusion Results are relevant to both clinicians and decision-makers. We confirmed the safety of PVZ. Use of PVZ increased steadily for children with miscellaneous conditions and medical complexity. Medical and social factors pose a risk for severe RIH and RSVH with accompanying burden of illness. A vaccine that protects against RSV is urgently required. Key Points

scholarly journals Does azithromycin modify viral load during severe respiratory syncytial virus bronchiolitis?

2015 ◽  
Vol 136 (4) ◽  
pp. 1129-1131 ◽  
Author(s):  
Avraham Beigelman ◽  
Leonard B. Bacharier ◽  
Jack Baty ◽  
Richard Buller ◽  
Sheila Mason ◽  
...  
Keyword(s):  
Viral Load ◽  
Respiratory Syncytial Virus ◽  
Severe Respiratory Syncytial Virus ◽  
Respiratory Syncytial Virus Bronchiolitis ◽  
Syncytial Virus
Sign in / Sign up

Export Citation Format

Share Document